Eli Lilly's Chief Executive Dave Ricks stated on Wednesday that the company opposes the White House's effort to legislate the "most favored nation" drug pricing model. Eli Lilly was among over a dozen pharmaceutical firms that signed agreements with the Trump administration last year, committing to align prescription drug prices in the U.S. with those in other wealthy nations. President Donald Trump has long argued that Americans pay excessively high drug prices, effectively subsidizing lower costs elsewhere in the world.
The pharmaceutical industry initially believed these agreements would address such concerns and prevent legislative attempts to codify the "most favored nation" pricing model. However, the White House has recently been urging Congress to enact parts of the agreement into law. Although the draft text has not been made public, the administration has indicated it is seeking support from drugmakers for this initiative.
Ricks expressed that Eli Lilly does not support this approach. "Once you throw it into the congressional process, what goes in is not what comes out," Ricks said. "I think we are seeing many people who would rather lower drug prices today without worrying about whether we will have new drugs tomorrow, whether the U.S. will maintain a robust pharmaceutical industry, and whether we can continue to conduct research and development in this country. I am concerned about these issues, which is why I do not believe this is a good idea. We have made our position very clear to both the administration and congressional leadership."
Ricks added that he believes the Trump administration and congressional leaders are listening to the company's concerns, but he emphasized that Eli Lilly will use "every tool at our disposal to oppose bad policy, which we believe this would be."
Comments